Tue, 30 Oct 2018 10:32:28 GMT
AstraZeneca to sell EU rights to Nexium to Grunenthal
AstraZeneca stated it was planning to sell its EU rights to Nexium, the acid-reflux medicine, to Grunenthal in a deal worth $700M in an upfront and $90M as the future sales-related payments.